[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10201809353TA - 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS - Google Patents

1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS

Info

Publication number
SG10201809353TA
SG10201809353TA SG10201809353TA SG10201809353TA SG10201809353TA SG 10201809353T A SG10201809353T A SG 10201809353TA SG 10201809353T A SG10201809353T A SG 10201809353TA SG 10201809353T A SG10201809353T A SG 10201809353TA SG 10201809353T A SG10201809353T A SG 10201809353TA
Authority
SG
Singapore
Prior art keywords
pyridin
ones
inhibitors
pyrazolo
pyrrolo
Prior art date
Application number
SG10201809353TA
Other languages
English (en)
Inventor
Andrew Combs
Thomas Maduskuie
Nikoo Falahatpisheh
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SG10201809353TA publication Critical patent/SG10201809353TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
SG10201809353TA 2014-04-23 2015-04-22 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS SG10201809353TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983289P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
SG10201809353TA true SG10201809353TA (en) 2018-11-29

Family

ID=53055117

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201809353TA SG10201809353TA (en) 2014-04-23 2015-04-22 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
SG11201608843TA SG11201608843TA (en) 2014-04-23 2015-04-22 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201608843TA SG11201608843TA (en) 2014-04-23 2015-04-22 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS

Country Status (36)

Country Link
US (7) US9540368B2 (fr)
EP (3) EP3674302B1 (fr)
JP (2) JP6572237B2 (fr)
KR (3) KR102702503B1 (fr)
CN (1) CN106414442B (fr)
AR (1) AR100160A1 (fr)
AU (3) AU2015249810B2 (fr)
BR (1) BR112016024626B1 (fr)
CA (1) CA2946731C (fr)
CL (1) CL2016002681A1 (fr)
CR (2) CR20200231A (fr)
CY (2) CY1122948T1 (fr)
DK (2) DK3134403T3 (fr)
EA (2) EA039678B1 (fr)
EC (1) ECSP16088983A (fr)
ES (2) ES2942723T3 (fr)
FI (1) FI3674302T3 (fr)
HR (2) HRP20230340T1 (fr)
HU (2) HUE061770T2 (fr)
IL (3) IL248415B (fr)
LT (2) LT3674302T (fr)
MA (1) MA39985B1 (fr)
ME (1) ME03763B (fr)
MX (2) MX2016013851A (fr)
MY (1) MY180775A (fr)
NZ (3) NZ725930A (fr)
PE (1) PE20170144A1 (fr)
PH (1) PH12016502115A1 (fr)
PL (2) PL3674302T3 (fr)
PT (2) PT3134403T (fr)
RS (2) RS64231B1 (fr)
SG (2) SG10201809353TA (fr)
SI (2) SI3134403T1 (fr)
TW (2) TWI672301B (fr)
UA (1) UA119870C2 (fr)
WO (1) WO2015164480A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909778T3 (es) 2013-03-15 2022-05-10 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de proteína BET para su uso en el tratamiento de una enfermedad proliferativa en combinación con un inhibidor de Janus quinasas
CA2917319A1 (fr) 2013-07-08 2015-01-15 Incyte Holdings Corporation Heterocycles tricycliques et inhibiteurs de proteines bet
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (fr) 2013-11-26 2015-06-04 Incyte Corporation Hétérocycles bicycliques servant d'inhibiteurs des protéines bet
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
WO2016044130A1 (fr) 2014-09-15 2016-03-24 Incyte Corporation Hétérocycles tricycliques utilisés en tant qu'inhibiteurs des protéines bet
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
CN107108613B (zh) 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途
WO2016123391A1 (fr) 2015-01-29 2016-08-04 Genentech, Inc. Composés thérapeutiques et leurs utilisations
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
EP3334717B1 (fr) 2015-08-11 2020-07-01 Neomed Institute Dihydroquinolinones substituées par un groupe aryle, leur préparation et leur utilisation comme agents pharmaceutiques
WO2017024406A1 (fr) * 2015-08-11 2017-02-16 Neomed Institute Lactames bicycliques n-substitués, leur préparation et leur utilisation en tant qu'agents pharmaceutiques
ES2904258T3 (es) 2015-08-12 2022-04-04 Neomed Inst Bencimidazoles sustituidos, su preparación y su uso como productos farmacéuticos
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
WO2017127930A1 (fr) 2016-01-28 2017-08-03 Neomed Institute [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments
RU2741808C2 (ru) 2016-04-15 2021-01-28 Эббви Инк. Ингибиторы бромодомена
FI3472157T3 (fi) * 2016-06-20 2023-06-01 Incyte Corp Bet-inhibiittorin kiteisiä kiinteitä muotoja
US20190284192A1 (en) 2016-11-10 2019-09-19 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof
TW201825490A (zh) * 2017-01-11 2018-07-16 大陸商江蘇豪森藥業集團有限公司 吡咯並［２，３－ｃ］吡啶類衍生物、其製備方法及其在醫藥上的應用
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． アデノシンアンタゴニストとしてのヘテロ環式化合物
CA3070073A1 (fr) 2017-07-18 2019-01-24 Nuvation Bio Inc. Composes de 1,8-naphthyridinone et leurs utilisations
EP3707139B1 (fr) 2017-11-06 2022-02-16 Centre National de la Recherche Scientifique Dérivés de xanthine et leurs utilisations en tant qu'inhibiteurs de bromodomaines de protéines bet
CA3086054A1 (fr) * 2017-12-20 2019-06-27 Betta Pharmaceuticals Co., Ltd Compose fonctionnant comme inhibiteur de proteine bromodomaine, et composition
EP4212515A1 (fr) 2017-12-21 2023-07-19 Ribon Therapeutics Inc. Quinazolinones en tant qu'inhibiteurs de parp14
WO2019154329A1 (fr) * 2018-02-06 2019-08-15 上海海和药物研究开发有限公司 Composé présentant une activité inhibitrice de bet, son procédé de préparation et son utilisation
CN110776508B (zh) * 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
CN109580433B (zh) * 2018-10-26 2021-05-28 中国辐射防护研究院 一种常规爆炸放射性气溶胶扩散的源项估算方法
JP2022509534A (ja) 2018-10-30 2022-01-20 ニューベイション・バイオ・インコーポレイテッド Ｂｅｔ阻害剤としてのヘテロ環式化合物
CN109432093A (zh) * 2018-12-23 2019-03-08 黄泳华 由吡唑并吡啶酮类化合物构成的乙酰胆碱酯酶抑制剂的增效体系
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150676A1 (fr) 2019-01-18 2020-07-23 Nuvation Bio Inc. Composés de 1,8-naphthyridinone et leurs utilisations
WO2020187123A1 (fr) * 2019-03-17 2020-09-24 上海凌达生物医药有限公司 Composé de pyrrole amidopyridone, son procédé de préparation et son utilisation
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
CN112094266B (zh) * 2019-06-17 2023-03-21 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
MA56513A (fr) * 2019-06-19 2022-04-27 Ribon Therapeutics Inc Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
CA3145827A1 (fr) 2019-07-02 2021-01-07 Nuvation Bio Inc. Composes heterocycliques utilises en tant qu'inhibiteurs de bet
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
AU2020412429A1 (en) 2019-12-27 2022-08-18 Lupin Limited Substituted tricyclic compounds
CA3184633A1 (fr) * 2020-06-03 2021-12-09 Incyte Corporation Polytherapie pour le traitement des neoplasies myeloproliferatives
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2021392700B2 (en) 2020-12-01 2023-11-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof
WO2022132049A1 (fr) * 2020-12-17 2022-06-23 National University Of Singapore Traitement de cancers à l'aide d'inhibiteurs de bet
CR20230402A (es) 2021-01-19 2023-11-21 Lupin Ltd Combinaciones farmacéuticas de inhibidores de sos1 para tratar o prevenir cancer
WO2024138201A2 (fr) * 2022-12-23 2024-06-27 Tay Therapeutics Limited Inhibiteurs de bet sélectifs et leurs utilisations

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2404E (fr) 1899-12-05 1904-03-26 Louis Olivier Victor Parmentie Machine à copier les lettres
JPS59170313A (ja) 1983-03-14 1984-09-26 Kurimoto Iron Works Ltd スクリ−ンゲ−ト
JPS6053449A (ja) 1983-09-01 1985-03-27 M K Seikou Kk 洗車機
JPS6085739U (ja) 1983-11-18 1985-06-13 クラリオン株式会社 テ−プレコ−ダにおけるピンチロ−ラ装置
JPS6243003U (fr) 1985-09-05 1987-03-14
JPH0314566A (ja) 1989-06-09 1991-01-23 Sankyo Co Ltd ベンズイミダゾール誘導体
US5244912A (en) 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof
FR2710915B1 (fr) 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
GB9410469D0 (en) 1994-05-25 1994-07-13 Erba Farmitalia Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation
FR2731708B1 (fr) 1995-03-13 1997-04-30 Synthelabo Derives de piperidine, leur procede de preparation et leur application en therapeutique
FR2747678B1 (fr) 1996-04-22 1998-05-22 Synthelabo Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
CN1450898A (zh) 2000-04-21 2003-10-22 法玛西雅厄普约翰美国公司 用于治疗纤维肌痛和慢性疲劳综合症的化合物
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
FR2816619B1 (fr) 2000-11-15 2003-01-31 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
ES2233671T3 (es) 2000-08-08 2005-06-16 Sanofi-Aventis Derivados de benzimidazol, su preparacion y aplicacion en terapeutica.
US6919334B2 (en) 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
JP3988830B2 (ja) 2002-11-22 2007-10-10 日本たばこ産業株式会社 縮合二環式窒素含有複素環
EP1462103A1 (fr) 2003-03-25 2004-09-29 Faust Pharmaceuticals Composés donneur de NO, produits de combinaison et utilisation en tant que modulateurs de libération de neurotransmetteurs
JPWO2005080334A1 (ja) 2004-02-23 2007-08-02 大日本住友製薬株式会社 新規ヘテロ環化合物
EP2522670A1 (fr) 2004-04-07 2012-11-14 Takeda Pharmaceutical Company Limited Antagonistes hétérocycliques des récépteurs du CRF
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
DE102005011058A1 (de) 2005-03-10 2006-09-14 Merck Patent Gmbh Substituierte Tetrahydro-pyrrolo-chinolinderivate
WO2006124874A2 (fr) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
KR20080035576A (ko) 2005-08-05 2008-04-23 아스트라제네카 아베 트리사이클릭 벤즈이미다졸 및 대사체 글루타메이트 수용체조절제로서 이들의 용도
EP2147310A4 (fr) 2007-04-27 2010-09-08 Univ Rochester Compositions et procédés permettant d'inhiber la signalisation de la protéine g
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009020559A2 (fr) 2007-08-03 2009-02-12 The J. David Gladstone Institutes Agents inhibant les interactions du p-tefb et leurs procédés d'utilisation
CA2710740C (fr) 2007-12-28 2016-07-19 Shinji Miyoshi Compose de thienotriazolodiazepine comme agent antitumoral
DE102008052618A1 (de) 2008-10-21 2010-04-22 Henkel Ag & Co. Kgaa Tricyclische Aldehyde und C,H-acide Verbindungen
US8669249B2 (en) 2009-03-27 2014-03-11 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
TW201105681A (en) 2009-06-10 2011-02-16 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
TW201103941A (en) 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
WO2011024987A1 (fr) 2009-08-31 2011-03-03 塩野義製薬株式会社 Dérivé hétérocyclique aromatique condensé et composition pharmaceutique associée
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
MX341212B (es) 2009-11-05 2016-08-11 Glaxosmithkline Llc * Inhibidor de bromodominio de benzodiazepina.
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2496945B1 (fr) 2009-11-05 2015-04-01 GlaxoSmithKline LLC Nouveau procédé
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
RS53179B (en) 2009-11-05 2014-06-30 Glaxosmithkline Llc BENZODIAZEPINSKI INHIBITOR BROMODOMENA
WO2011133722A2 (fr) 2010-04-23 2011-10-27 Kineta, Inc. Composés antiviraux
WO2011143651A1 (fr) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions et procédés permettant de moduler un métabolisme
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
JP6022442B2 (ja) 2010-05-14 2016-11-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 男性用避妊組成物および使用方法
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
WO2012075456A1 (fr) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Inhibiteurs de bromodomaines et leurs utilisations
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
MX2013008822A (es) 2011-02-09 2013-10-07 Hoffmann La Roche Compuestos heterociclicos como inhibidores de cinasa fosfatidilinositol-3 (pi3).
CA2828212A1 (fr) 2011-02-23 2012-08-30 Shiraz Mujtaba Inhibiteurs de bromodomaines comme modulateurs d'expression genique
MX340013B (es) 2011-03-21 2016-06-22 Hoffmann La Roche Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2012174487A2 (fr) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Inhibiteurs à bromodomaine et leurs utilisations
US20150197497A1 (en) 2011-06-24 2015-07-16 Dana-Farber Cancer Institute, Inc. Selective inhibitors of histone deacetylase isoform 6 and methods thereof
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
CA2843643A1 (fr) 2011-07-29 2013-02-07 The Children's Hospital Of Philadelphia Compositions et methodes de traitement du vih
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (fr) 2011-08-22 2013-02-28 Pfizer Inc. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine
WO2013033269A1 (fr) 2011-08-29 2013-03-07 Coferon, Inc. Monomères bioorthogonaux capables de se dimériser et de cibler des bromodomaines et procédés d'utilisation correspondant
WO2013033268A2 (fr) 2011-08-29 2013-03-07 Coferon, Inc. Ligands bromodomaines bivalents et procédés d'utilisation de ceux-ci
KR101996697B1 (ko) 2011-08-31 2019-07-04 오쓰까 세이야꾸 가부시키가이샤 퀴놀론 화합물
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013043553A1 (fr) 2011-09-22 2013-03-28 Glaxosmithkline Llc Composés pyrrolopyridinones et méthodes de traitement du vih
WO2013044511A1 (fr) 2011-09-30 2013-04-04 沈阳蓝桑医药生物技术研发有限公司 Composition pharmaceutique contenant du riligustilide et utilisation associée
EP2771340B1 (fr) 2011-10-25 2016-04-13 Sanofi Dérivés d'amide de l'acide 6-(4-hydroxy-phényl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinases
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
WO2013097052A1 (fr) 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
EP2830629A4 (fr) 2012-03-28 2016-01-20 Icahn School Of Medicine Mount Sinai Compositions et procédés pour réactiver un virus d'immunodéficience latent
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281396A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
WO2013155695A1 (fr) 2012-04-20 2013-10-24 Abbott Laboratories Dérivés d'iso-indolone
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
JP6215315B2 (ja) 2012-06-12 2017-10-18 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
RU2659171C2 (ru) 2012-06-25 2018-06-28 Онкоэтикс Гмбх Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения
US9610332B2 (en) 2012-07-18 2017-04-04 Massachusetts Institute Of Technology Compositions and methods for modulating BRD4 bioactivity
WO2014026997A1 (fr) 2012-08-16 2014-02-20 Bayer Pharma Aktiengesellschaft 2,3-benzodiazépines
EP2884983B1 (fr) 2012-08-16 2017-10-04 GlaxoSmithKline LLC Benzodiazepines pour traiter le carcinome pulmonaire à petites cellules
CA2885944A1 (fr) 2012-09-28 2014-05-08 Oncoethix Sa Formulation pharmaceutique contenant des composes thienotriazolodiazepine
JP6276277B2 (ja) 2012-09-28 2018-02-07 バイエル ファーマ アクチエンゲゼルシャフト Ｂｅｔタンパク質阻害性の５−アリールトリアゾロアゼピン
PT2917181T (pt) 2012-11-09 2020-01-08 Medicines For Malaria Venture Mmv Derivados de heteroarilo e suas utilizações
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9663533B2 (en) 2012-11-14 2017-05-30 Glaxosmithkline Llc Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
WO2014095775A1 (fr) 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Dihydrochinoxalinones inhibitrices de protéine bet
CA2895404A1 (fr) 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Dihydropyridopyrazinones inhibitrices de proteine bet
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
WO2014128655A1 (fr) 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Dérivés d'imidazo[4,5-c]quinoléine substituée utilisés comme inhibiteurs de bromodomaines
US10053454B2 (en) 2013-02-27 2018-08-21 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US8980879B2 (en) 2013-03-11 2015-03-17 Abbvie Inc. Bromodomain inhibitors
AU2014249025A1 (en) 2013-03-11 2015-09-17 Abbvie Inc. Bromodomain inhibitors
EP2970312B1 (fr) 2013-03-11 2017-11-15 The Regents of The University of Michigan Inhibiteurs de bromodomaines bet et méthodes thérapeutiques les utilisant
WO2014139324A1 (fr) 2013-03-12 2014-09-18 Abbvie Inc. Inhibiteurs de bromodomaines tétracycliques
JP2016512542A (ja) 2013-03-12 2016-04-28 アッヴィ・インコーポレイテッド ピロールアミド阻害剤
EP2970276A1 (fr) 2013-03-12 2016-01-20 AbbVie Inc. Inhibiteurs de bromodomaine dihydro-pyrrolopyridinone
WO2014159392A1 (fr) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Réactifs de liaison à des bromodomaines et leurs utilisations
WO2014140077A1 (fr) 2013-03-14 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Furopyridines utilisées en tant qu'inhibiteurs de bromodomaine
WO2014159837A1 (fr) 2013-03-14 2014-10-02 Convergene Llc Procédés et compositions pour l'inhibition de protéines contenant un bromodomaine
DK2970127T3 (en) 2013-03-14 2019-01-28 Glaxosmithkline Ip No 2 Ltd 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND USE THEREOF AS BROOMDOMONE INHIBITORS
EP2970265B1 (fr) 2013-03-15 2018-08-08 Plexxikon Inc. Composés hétérocycliques et leurs utilisations
ES2909778T3 (es) 2013-03-15 2022-05-10 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de proteína BET para su uso en el tratamiento de una enfermedad proliferativa en combinación con un inhibidor de Janus quinasas
WO2014152029A2 (fr) 2013-03-15 2014-09-25 Epigenetix, Inc. Composés d'oxazolo[5,4-c] quinolin-2-one en tant qu'inhibiteurs de bromodomaines
JP6453845B2 (ja) 2013-03-27 2019-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｒｄ４阻害薬としてのジヒドロキナゾリノン類似体
JP6370368B2 (ja) 2013-03-27 2018-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｒｄ４阻害剤としてのインドリノン類似体
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
WO2014170350A1 (fr) 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Composés destinés à être utilisés comme inhibiteurs de bromodomaine
BR112015027130A2 (pt) 2013-04-26 2018-07-24 Beigene Ltd 5-(3,5-dimetilisoxazol-4-il)indolin-2-ona substituído
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
BR112015029491A2 (pt) 2013-05-27 2017-07-25 Novartis Ag derivados de imidazopirrolidinona e seu uso no tratamento de doença
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
JP2016520118A (ja) 2013-05-28 2016-07-11 ノバルティス アーゲー Ｂｅｔ阻害剤としてのピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用
CA2915419A1 (fr) 2013-06-17 2014-12-24 Bayer Pharma Aktiengesellschaft Phenyl-2,3-benzodiasepine substituee
ITMI20130991A1 (it) 2013-06-17 2014-12-18 Industrie De Nora Spa Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse.
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
AR096758A1 (es) 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
WO2014206150A1 (fr) 2013-06-28 2014-12-31 Abbvie Inc. Inhibiteurs de bromodomaine
CA2917319A1 (fr) 2013-07-08 2015-01-15 Incyte Holdings Corporation Heterocycles tricycliques et inhibiteurs de proteines bet
CA2917177C (fr) 2013-07-16 2022-07-12 Basf Se Azines herbicides
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
KR101672096B1 (ko) 2013-09-30 2016-11-02 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
SI3057586T1 (sl) 2013-10-18 2020-04-30 Celgene Quanticel Research, Inc. Inhibitorji bromodomene
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US20150148372A1 (en) 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081203A1 (fr) 2013-11-26 2015-06-04 Incyte Corporation Hétérocycles bicycliques servant d'inhibiteurs des protéines bet
CN105939996A (zh) 2013-12-09 2016-09-14 艾伯维公司 用作布罗莫结构域抑制剂的二氢吡啶酮和二氢哒嗪酮衍生物
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
ES2687497T3 (es) 2014-01-09 2018-10-25 Orion Corporation Derivados bicíclicos heterocíclicos como inhibidores de bromodominio
AU2015222887B2 (en) 2014-02-28 2019-06-27 The Regents Of The University Of Michigan 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
EP3134386B1 (fr) 2014-04-23 2020-05-20 Takeda Pharmaceutical Company Limited Dérivés i isoindoline-1-one à activité de modulateur alloestérique positif du récepteur m1 muscarinique cholinergique pour le traitement de la maladie d'alzheimer
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
CA2944277C (fr) 2014-04-23 2022-12-13 Basf Se Composes de diaminotriazine en tant qu'herbicides
AU2015252844A1 (en) 2014-05-02 2016-11-03 Kay NOEL Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
CN106687117A (zh) 2014-05-02 2017-05-17 翁科埃斯克斯有限公司 利用噻吩并三唑并二氮杂*化合物治疗耐受性非霍奇金淋巴瘤、髓母细胞瘤和/或alk+非小细胞肺癌的方法
CA2947970A1 (fr) 2014-05-08 2015-11-12 Oncoethix Gmbh Methode de traitement du cancer du sein triple negatif a l'aide de composes de thienotriazolodiazepine
WO2015169953A1 (fr) 2014-05-08 2015-11-12 Oncoethix Gmbh Méthode de traitement d'un gliome à l'aide de composés thiénotriazolodiazépine
EP3148543B1 (fr) 2014-05-30 2020-04-08 Icahn School of Medicine at Mount Sinai Petites molécules en tant que modulateurs de la transcription de bromodomaines
LT3157928T (lt) 2014-06-20 2019-05-27 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos
WO2016044130A1 (fr) 2014-09-15 2016-03-24 Incyte Corporation Hétérocycles tricycliques utilisés en tant qu'inhibiteurs des protéines bet
RS60629B1 (sr) 2014-10-24 2020-09-30 Bristol Myers Squibb Co Jedinjenja indol karboksamida korisna kao inhibitori kinaze
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
US10259809B2 (en) 2015-02-03 2019-04-16 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
WO2016186453A1 (fr) 2015-05-20 2016-11-24 Kainos Medicine, Inc. Dérivés de quinoléine à utiliser en tant qu'inhibiteurs de bromodomaine
RU2720145C2 (ru) 2015-05-29 2020-04-24 Сионоги Энд Ко., Лтд. Азотсодержащие трициклические производные, обладающие активностью ингибирования репликации вич
CN105039258B (zh) 2015-07-03 2018-04-17 北京大学 将非神经元细胞重编程为神经元样细胞的方法和组合物
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
CN105254635A (zh) 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
US20170127985A1 (en) 2015-11-11 2017-05-11 Medtronic Minimed, Inc. Sensor set
WO2017103670A1 (fr) 2015-12-14 2017-06-22 Zenith Epigenetics Lid. Inhibiteurs hétérocycliques 1h-imidazo[4,5-b]pyridinyle et 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyle de protéine à bromodomaines bet
WO2017127930A1 (fr) 2016-01-28 2017-08-03 Neomed Institute [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments
WO2017133681A1 (fr) 2016-02-05 2017-08-10 正大天晴药业集团股份有限公司 Composé tricyclique pour inhibiteur de protéine contenant un bromodomaine et préparation, composition pharmaceutique et son utilisation
FI3472157T3 (fi) 2016-06-20 2023-06-01 Incyte Corp Bet-inhibiittorin kiteisiä kiinteitä muotoja
CN108069958A (zh) 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用

Also Published As

Publication number Publication date
BR112016024626B1 (pt) 2023-03-21
US9540368B2 (en) 2017-01-10
EP3134403B1 (fr) 2020-02-12
JP2019206584A (ja) 2019-12-05
EP3674302A1 (fr) 2020-07-01
BR112016024626A8 (pt) 2023-01-24
TW201938559A (zh) 2019-10-01
CN106414442B (zh) 2019-03-15
LT3674302T (lt) 2023-06-12
PT3674302T (pt) 2023-05-10
AU2015249810A8 (en) 2016-11-24
NZ725930A (en) 2023-04-28
JP6572237B2 (ja) 2019-09-04
AU2015249810B2 (en) 2019-04-18
CY1126052T1 (el) 2023-11-15
UA119870C2 (uk) 2019-08-27
IL281263B (en) 2021-09-30
PT3134403T (pt) 2020-05-18
WO2015164480A1 (fr) 2015-10-29
PL3674302T3 (pl) 2023-07-24
RS60139B1 (sr) 2020-05-29
EP3674302B1 (fr) 2023-03-01
TWI672301B (zh) 2019-09-21
KR102430144B1 (ko) 2022-08-08
IL273049B (en) 2021-03-25
US20240002381A1 (en) 2024-01-04
AU2021200450A1 (en) 2021-02-25
US20200048251A1 (en) 2020-02-13
PH12016502115B1 (en) 2017-01-16
RS64231B1 (sr) 2023-06-30
KR20220113552A (ko) 2022-08-12
US10472358B2 (en) 2019-11-12
MX2016013851A (es) 2017-07-14
AU2015249810A1 (en) 2015-10-29
AR100160A1 (es) 2016-09-14
AU2019205984A1 (en) 2019-08-01
PH12016502115A1 (en) 2017-01-16
US20200377502A1 (en) 2020-12-03
US11059821B2 (en) 2021-07-13
EP3134403A1 (fr) 2017-03-01
EA039678B1 (ru) 2022-02-24
TW201625607A (zh) 2016-07-16
CA2946731C (fr) 2022-06-07
CR20200231A (es) 2020-09-11
IL248415B (en) 2020-03-31
US20210300925A1 (en) 2021-09-30
KR20160145796A (ko) 2016-12-20
EA034972B1 (ru) 2020-04-13
NZ763737A (en) 2023-04-28
JP2017513879A (ja) 2017-06-01
AU2021200450B2 (en) 2022-08-04
US10781209B2 (en) 2020-09-22
KR20240134245A (ko) 2024-09-06
MY180775A (en) 2020-12-09
DK3674302T3 (da) 2023-04-03
MX2020011035A (es) 2020-10-28
US20170158689A1 (en) 2017-06-08
SI3674302T1 (sl) 2023-07-31
JP6745390B2 (ja) 2020-08-26
HUE061770T2 (hu) 2023-08-28
SI3134403T1 (sl) 2020-07-31
FI3674302T3 (fi) 2023-04-27
TWI735002B (zh) 2021-08-01
PE20170144A1 (es) 2017-03-16
IL248415A0 (en) 2016-11-30
PL3134403T3 (pl) 2020-07-13
DK3134403T3 (en) 2020-03-09
ME03763B (fr) 2021-04-20
LT3134403T (lt) 2020-05-11
EA201692134A1 (ru) 2017-02-28
SG11201608843TA (en) 2016-11-29
CR20160542A (es) 2017-04-25
EP4218766A1 (fr) 2023-08-02
US9957268B2 (en) 2018-05-01
HUE049627T2 (hu) 2020-09-28
IL273049A (en) 2020-04-30
IL281263A (en) 2021-04-29
ES2784846T3 (es) 2020-10-01
CA2946731A1 (fr) 2015-10-29
HRP20230340T1 (hr) 2023-06-09
EA202090371A1 (ru) 2020-06-30
ES2942723T3 (es) 2023-06-06
MA39985B1 (fr) 2020-03-31
CL2016002681A1 (es) 2017-02-03
CN106414442A (zh) 2017-02-15
HRP20200564T1 (hr) 2020-06-26
US20180312506A1 (en) 2018-11-01
ECSP16088983A (es) 2017-05-31
CY1122948T1 (el) 2021-10-29
US11702416B2 (en) 2023-07-18
AU2019205984B2 (en) 2020-10-29
KR102702503B1 (ko) 2024-09-05
US20150307493A1 (en) 2015-10-29
NZ763740A (en) 2023-06-30
BR112016024626A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
PH12016502115A1 (en) 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
PH12019502318A1 (en) Trycyclic heterocycles as bet protein inhibitors
TW201613935A (en) Tricyclic heterocycles as BET protein inhibitors
EP3107914B8 (fr) Pyrazolo[1,5-a]pyrimidine-5,7-diamines en tant qu'inhibiteurs de cdk et leur utilisation thérapeutique
WO2014152029A3 (fr) Composés d'oxazolo[5,4-c] quinolin-2-one en tant qu'inhibiteurs de bromodomaines
TH182466B (th) สารกลุ่ม 1เอช-ไพร์โรโล[2,3-ซี]ไพริดิน-7(6เอช)-โอน และไพราโซโล[3,4-ซี] ไพริดิน-7(6เอช)-โอน ที่เป็นตัวยับยั้งของโปรตีน bet
TH182466A (th) สารกลุ่ม 1เอช-ไพร์โรโล[2,3-ซี]ไพริดิน-7(6เอช)-โอน และไพราโซโล[3,4-ซี] ไพริดิน-7(6เอช)-โอน ที่เป็นตัวยับยั้งของโปรตีน bet